Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 Nov;67(6):406–419. doi: 10.1016/j.curtheres.2006.12.005

Plasma levels, tissue distribution, and excretion of radioactivity after single-dose administration of (3H)-oleic acid added to D-004, a lipid extract of the fruit of Roystonea regia, in rats

L Yohani Pérez 1,*, Roberto Menéndez 1, Rosa Más 1, Rosa M González 1
PMCID: PMC3965973  PMID: 24678113

Abstract

Background:

D-004, a lipid extract of the fruit of Roystonea regia, contains a mixture of fatty acids—mainly oleic, lauric, palmitic, and myristic acids, with oleic acid being among the most abundant—that has been found to reduce the risk for prostatic hyperplasia (PH) induced with testosterone (T) in rats. The pharmacokinetic profile of D-004 has not been reported.

Objective:

The objective of this study in rats was to assess plasma levels, tissue distribution, and excretion of total radioactivity (TR) after single-dose administration of oral D-004 radiolabeled with (3H)-oleic acid, as a surrogate for the pharmacokinetics of D-004.

Methods:

This experimental study was conducted at the Pharmacology Department, Center of Natural Products, National Center for Scientific Research, Havana, Cuba. Single doses of suspensions of (3H)-oleic acid 0.16 μCi/mg mixed with D-004 400 mg/kg (radioactive dose/animal 7.2 μCi) were given orally to male Wistar rats weighing 150 to 200 g assigned to the treated or control group. Three rats were euthanized at each of the following times: 0.25, 0.5, 1, 1.5, 2, 4, 8, 24, 48, 72, 96, and 144 hours after study drug administration. After administration, the rats euthanized at the last experimental time point were housed individually in metabolism cages. Urine and feces samples were collected daily. At each time point, blood samples were drawn and plasma samples were obtained using centrifugation. After euthanization, tissue samples (liver, lungs, spleen, brain, kidneys, adipose tissue, muscle, stomach, small and large intestines, adrenal glands, heart, testes, prostate, and seminal vesicles) were quickly removed, washed, blotted, and homogenized. Plasma (100 μL), tissue aliquots (100 mg), feces (10 mg), and urine (100μL) were dissolved and TR was measured. Samples were assayed in duplicate. Results were expressed in μgEq of radio-labeled oleic acid per milliliter of plasma or urine or gram of tissue or feces. Plasma, tissue, feces, and urine samples of rats that did not receive (3H)-oleic acid were used as controls. Excretion was expressed as the percentage of the radioactivity excreted via each route with respect to the total radioactive dose administered to each rat.

Results:

A total of 50 rats were included in the experiment (mean age, 4 weeks; mean weight, 310 g). Absorption was rapid; mean Cmax was 195.56 (31.12) μgEq/mL, and mean Tmax was 2 hours. Thereafter, a biphasic decay of TR was found: a rapid first phase (t1/2α, 1.33 hours), followed by a slower second elimination phase (t1/2β, 36.07 hours). Radioactivity was rapidly and broadly distributed throughout the tissues, with more accumulating in the prostate than elsewhere. In the first 8 hours, accumulation of TR was greatest in the prostate, followed by the liver, small intestine, and plasma. Subsequently, TR increased in the small intestine, while it decreased in the liver and plasma. In contrast, over the periods of 24 and 144 hours after administration, TR increased in the adipose tissue, while it decreased in the other tissues and plasma. During those intervals, TR was greatest in the prostate, followed by adipose tissue. Mean peak radioactivity in the prostate (562.41 μgEq/g) was reached at 4 hours and decreased slowly thereafter. The prostate had the highest values of t1/2β and cumulative AUC compared with the other tissues and plasma. Mean (SD) TR was similar in feces (33.48% [4.90%]) and urine (28.96% [5.32%]), with total excretion being 62.40% (5.90%) of the administered dose.

Conclusions:

In this experimental study, after single-dose administration of oral D-004 radiolabeled with (3H)-oleic acid in rats, TR was rapidly and widely distributed across the tissues, with the prostate having the highest accumulation of radioactivity. Excretion of TR was limited, with similar amounts being excreted in feces and urine. The broad distribution of radiolabeled oleic acid and/or its metabolites suggests (SD) pharmacokinetic rationale for the effectiveness of D-004 in reducing the risk for PH induced with T in rats.

Key words: oleic acid pharmacokinetics, D-004, Roystonea regia lipid extract, royal palm lipid extract

Full Text

The Full Text of this article is available as a PDF (699.2 KB).

References

  • 1.Clifford G.M., Farmer R.D. Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur Urol. 2000;38:2–19. doi: 10.1159/000020246. [DOI] [PubMed] [Google Scholar]
  • 2.Simpson R.J. Benign prostatic hyperplasia. An overview of epidemiology and treatment. Primary Care in the New NHS. 2001:184–186. [Google Scholar]
  • 3.Barry M.J., Roehrborn C.G. Benign prostatic hyperplasia. BMJ. 2001;323:1042–1046. doi: 10.1136/bmj.323.7320.1042. [published correction appears in BMJ. 2002;324:775] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Thorpe A., Neal D. Benign prostatic hyperplasia. Lancet. 2003;361:1359–1367. doi: 10.1016/S0140-6736(03)13073-5. [published correction appears in Lancet. 2003;362:496] [DOI] [PubMed] [Google Scholar]
  • 5.Bhargava S., Canda A.E., Chapple C.R. A rational approach to benign prostatic hyperplasia evaluation: Recent advances. Curr Opin Urol. 2004;14:1–6. doi: 10.1097/00042307-200401000-00001. [DOI] [PubMed] [Google Scholar]
  • 6.Sandhu J.S., Te A.E. The role of 5 alpha-reductase inhibition as monotherapy in view of the MTOPS data. Curr Urol Rep. 2004;5:274–279. doi: 10.1007/s11934-004-0050-6. [DOI] [PubMed] [Google Scholar]
  • 7.Oelke M., Hofner K., Berges R.R., Jonas U. Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results [in German] Urologe A. 2002;41:425–441. doi: 10.1007/s00120-002-0236-9. [DOI] [PubMed] [Google Scholar]
  • 8.Lowe F.C., Dreikorn K., Borkowski A. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate. 1998;37:187–193. doi: 10.1002/(sici)1097-0045(19981101)37:3<187::aid-pros8>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  • 9.Plosker G.L., Brogden R.N. Serenoa repens (permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379–395. doi: 10.2165/00002512-199609050-00008. [DOI] [PubMed] [Google Scholar]
  • 10.Bombardelli E., Morazzoni P., Small J.K. Serenoa repens (bartram) Fitoterapia. 1997;68:99–113. [Google Scholar]
  • 11.Wilt T.J., Ishani A., Stark G. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA. 1998;280:1604–1609. doi: 10.1001/jama.280.18.1604. [published correction appears in JAMA. 1999;281: 515] [DOI] [PubMed] [Google Scholar]
  • 12.WHO monographs on selected medicinal plants. 2000. Fructus Serenoa repentis; pp. 285–299. [Google Scholar]
  • 13.Vol. 28. Pharmacopeial Convention; Rockville, Md: 2005. Saw palmetto extract; p. 425. (Expert Committee. United States pharmacopeial forum: (DSB) dietary supplement: Botanicals). No. 2. Publication no. USP28-NF23. [Google Scholar]
  • 14.Wilt T., Ishani A., Stark G. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001423. doi: 10.1002/14651858.CD001423. [DOI] [PubMed] [Google Scholar]
  • 15.Aliaev I.G., Vinarov A.Z., Lokshin K.L., Spivak L.G. Five-year experience in treating patients with permixone (Serenoa repens “Pierre Fabre Medicament”) [in Russian] Urologiia. 2002;1:23–25. [PubMed] [Google Scholar]
  • 16.Gordon A.E., Shaughnessy A.F. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67:1281–1283. [PubMed] [Google Scholar]
  • 17.Chevalier G., Benard P., Cousse H., Bengone T. Distribution study of radioactivity in rats after oral administration of the lipido/sterolic extract of Serenoa repens (permixon) supplemented with [1-14C]-lauric acid, [1-14C]-oleic acid or [4-14C]-betasitosterol. Eur J Drug Metab Pharmacokinet. 1997;22:73–83. doi: 10.1007/BF03189787. [DOI] [PubMed] [Google Scholar]
  • 18.De Bernardi Di Valserra M., Tripodi A.S., Contos S., Germogli R. Serenoa repens capsules: A bioequivalence study. Acta Toxicol Ther. 1994;15:21–39. [Google Scholar]
  • 19.Arruzazabala M.L., Carbajal D., Mas R. Preventive effects of D-004, a lipid extract from Cuban royal palm (Roystonea regia) fruits, on testosterone-induced prostate hyperplasia in intact and castrated rodents. Drugs Exp Clin Res. 2004;30:227–233. [PubMed] [Google Scholar]
  • 20.Carbajal D., Arruzazabala M.D.L., Más R. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostate hypertrophy induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr Ther Res Clin Exp. 2004;65:505–514. doi: 10.1016/j.curtheres.2005.01.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Noa M., Arruzazabala M.L., Carbajal D. Effect of D-004, a lipid extract from Cuban royal palm fruit, on histological changes of prostate hyperplasia induced with testosterone in rats. Int J Tissue React. 2005;27:203–211. [PubMed] [Google Scholar]
  • 22.Carbajal D., Molina V., Mas R., Arruzazabala M.L. Therapeutic effect of D-004, a lipid extract from Roystonea regia fruits, on prostate hyperplasia induced in rats. Drugs Exp Clin Res. 2005;31:193–197. [PubMed] [Google Scholar]
  • 23.Raynaud J.P., Cousse H., Martin P.M. Inhibition of type 1 and type 2 5alpha-reductase activity by free fatty acids, active ingredients of permixon. J Steroid Biochem Mol Biol. 2002;82:233–239. doi: 10.1016/s0960-0760(02)00187-5. [DOI] [PubMed] [Google Scholar]
  • 24.Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein. J Clin Invest. 1988;82:2001–2010. doi: 10.1172/JCI113820. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Stahl A., Hirsch D.J., Gimeno R.E. Identification of the major intestinal fatty acid transport protein. Mol Cell. 1999;4:299–308. doi: 10.1016/s1097-2765(00)80332-9. [DOI] [PubMed] [Google Scholar]
  • 26.Chaves C.R., Elias P.R., Cheng W. Long chain fatty acid uptake by human intestinal mucosa in vitro: Mechanisms of transport. Digestion. 2003;67:32–36. doi: 10.1159/000069700. [DOI] [PubMed] [Google Scholar]
  • 27.Murota K., Matsui N., Kawada T. Influence of fatty alcohol and other fatty acid derivatives on fatty acid uptake into rat intestinal epithelial cells. Lipids. 2001;36:21–26. doi: 10.1007/s11745-001-0663-2. [DOI] [PubMed] [Google Scholar]
  • 28.Holehouse E.L., Liu M.L., Aponte G.W. Oleic acid distribution in small intestinal epithelial cells expressing intestinal-fatty acid binding protein. Biochern Biophys Acta. 1998;1390:52–64. doi: 10.1016/s0005-2760(97)00176-8. [DOI] [PubMed] [Google Scholar]
  • 29.Schwieterman W., Sorrentino D., Potter B.J. Vol. 85. 1988. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut; pp. 359–363. (Proc Natl Acad Sci USA). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Rabinowitz J.L., Myerson R.M. Changes in the lipid content of rat lymph after the ingestion of [14C] long-chain fatty acids. Life Sci. 1994;54:555–559. doi: 10.1016/0024-3205(94)90006-x. [DOI] [PubMed] [Google Scholar]
  • 31.Bookstaff R.C., PaiBir S., Bharaj S.S. The safety and the use of ethyl oleate in food is supported by metabolism data in rats and clinical safety data in humans. Regul Toxicol Pharmacol. 2003;37:133–148. doi: 10.1016/s0273-2300(02)00043-0. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES